V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009234 | 330006036 | null | 73.6 | Palliative (P) | 2016-08-29 | 2016-09-12 | AML Int Guide ADE 8+3+5 (2) | N | null | 330007702 | TRASTUZUMAB |
| 330009235 | 330006038 | null | 72.5 | Curative (C) | 2019-01-16 | 2019-01-16 | Doxorubicin + Methotrexate | N | null | 330007777 | CETUXIMAB + CISPLATIN + FU |
| 330009236 | 330006038 | 0 | 75.9 | Palliative (P) | 2017-02-16 | 2017-02-16 | STS Rhabdomyosarcoma RMS 2005 IVA | Y | N | 330007777 | VINCRISTINE |
| 330009237 | 330006041 | 0.82 | 67.7 | null | 2018-12-22 | 2019-01-14 | CISPLATIN + VINORELBINE | null | null | 330008362 | CAPECITABINE + IRINOTECAN |
| 330009238 | 330006042 | 1.77 | 54 | Curative (C) | 2015-01-20 | 2015-01-20 | IBRUTINIB | N | null | 330008837 | CYTARABINE |
| 330009239 | 330009290 | 1.6 | 24.5 | Curative (C) | 2018-11-03 | 2018-12-28 | EMA/CO | N | N | 330008837 | CYTARABINE |
| 330009240 | 330006043 | null | 80 | Neo-adjuvant (N) | 2017-03-08 | 2017-03-09 | IVA | 01 | N | 330009558 | HYDROXYCARBAMIDE |
| 330009241 | 330006044 | 1.65 | null | Palliative (P) | 2018-06-25 | 2018-07-01 | Ifosfamide 3g/m2 5 day | 2 | N | 330009579 | DHAP |
| 330009242 | 330006047 | 0 | null | Disease modification (D) | null | 2013-12-31 | CHLORAMBUCIL + OFATUMUMAB | null | null | 330009587 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330009243 | 330006049 | 1.69 | 71.6 | Curative (C) | 2017-03-16 | 2017-03-16 | IMATINIB | N | N | 330009636 | BUSULFAN + MELPHALAN |
| 330009244 | 330006050 | 1.82 | null | Palliative (P) | 2019-02-24 | 2019-03-16 | Ifosfamide | N | N | 330009744 | CAPECITABINE + CARBOPLATIN |
| 330009245 | 330009293 | 1.81 | 17.6 | Adjuvant (A) | 2018-02-15 | 2018-02-18 | BEP 5 Day | 02 | null | 330009760 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330009246 | 330006051 | 1.45 | 55 | Neo-adjuvant (N) | null | 2018-06-11 | IPO | null | null | 330009817 | MPT |
| 330009247 | 330009294 | 0 | null | Curative (C) | 2016-01-29 | 2016-02-03 | Cytarabine+Methotrexate Intrathecal | 02 | N | 330009845 | IRINOTECAN + MDG |
| 330009248 | 330009294 | 1.67 | 98.4 | Curative (C) | null | 2015-11-08 | CVP | N | N | 330009845 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330009249 | 330009294 | 1.69 | 16.1 | Curative (C) | 2018-01-14 | 2018-01-15 | CAP | N | N | 330009845 | CISPLATIN + FLUOROURACIL + RT |
| 330009250 | 330006052 | 1.6 | 8.8 | Curative (C) | 2013-08-31 | 2013-08-31 | Mitotane 5g | Y | N | 330009954 | CYTARABINE |
| 330009251 | 330006053 | 1.67 | null | Curative (C) | 2017-08-26 | 2017-08-30 | Ifosfamide | 02 | N | 330010099 | CLADRIBINE |
| 330009252 | 330006053 | 1.74 | 71.6 | Palliative (P) | 2017-07-19 | 2017-07-19 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | null | N | 330010099 | BEVACIZUMAB + IRINOTECAN |
| 330009253 | 330009297 | 1.85 | 96 | Palliative (P) | 2015-06-10 | 2015-07-13 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 330010223 | ALDESLEUKIN |
| 330009254 | 330006058 | 0 | 98.2 | Curative (C) | null | 2017-03-17 | BUSULFAN + FLUDARABINE | N | N | 330010514 | BEVACIZUMAB + IRINOTECAN |
| 330009255 | 330006062 | 1.62 | 10.6 | Palliative (P) | 2016-05-02 | 2016-05-18 | Cytarabine Intrathecal (any age) | N | N | 330010555 | EMA/CO |
| 330009256 | 330006063 | 1.71 | 83.8 | Palliative (P) | 2015-02-27 | 2015-02-27 | CISPLATIN + GEMCITABINE | N | N | 330010809 | PONATINIB |
| 330009257 | 330006065 | 1.73 | 71.5 | null | 2017-07-08 | 2018-04-02 | CHLORAMBUCIL + RITUXIMAB | N | N | 330010873 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE |
| 330009258 | 330006067 | null | 77.25 | Adjuvant (A) | 2018-03-31 | 2018-05-20 | CNS LGG Irinotecan & Bevacizumab | N | Y | 330010913 | FCR |
| 330009259 | 330009301 | 1.77 | 48.9 | Curative (C) | null | 2015-01-19 | Cisplatin + Gemcitabine (D 1 & 8) | null | N | 330011047 | CAPECITABINE + CARBOPLATIN |
| 330009260 | 330006068 | 1.62 | 107 | Palliative (P) | 2018-06-21 | 2018-07-12 | Hydroxycarbamide | N | N | 330011080 | CHOP R |
| 330009261 | 330009304 | null | 75.7 | null | 2018-01-16 | 2018-02-28 | Dox + HD Mtx (post PAM) | N | N | 330011114 | IVA |
| 330009262 | 330006071 | 1.87 | 77.9 | Palliative (P) | 2013-12-03 | 2014-04-14 | IBRUTINIB | 01 | null | 330011302 | BEP |
| 330009263 | 330006072 | 1.68 | null | Palliative (P) | 2017-08-18 | 2017-08-19 | Imatinib 400mg | 2 | N | 330011853 | DACTINOMYCIN |
| 330009264 | 330006073 | 1.8 | 86 | Palliative (P) | 2016-06-26 | 2016-08-08 | AML Int Guide ADE 10+3+5 (1) | N | null | 330011879 | CARBOPLATIN + THIOTEPA + TOPOTECAN |
| 330009265 | 330009307 | 0 | null | Curative (C) | 2016-09-30 | 2016-09-30 | VDC | 02 | N | 330011918 | MAP + MIFAMURTIDE |
| 330009266 | 330006074 | null | 8.4 | Palliative (P) | 2014-06-28 | 2014-08-25 | FLUOROURACIL | N | N | 330011954 | VDC |
| 330009267 | 330006075 | null | 60.05 | Neo-adjuvant (N) | 2018-03-26 | 2018-07-30 | CNS LGG Irinotecan & Bevacizumab | N | N | 330011961 | CASPS TRIAL |
| 330009268 | 330009309 | 1.72 | 73.9 | null | null | 2018-11-05 | CARBOPLATIN + CETUXIMAB + FU | null | null | 330012069 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330009269 | 330006077 | 0 | 73.9 | Palliative (P) | 2016-09-30 | 2016-09-30 | Topotecan (intravenous) | N | N | 330012226 | CAPECITABINE |
| 330009270 | 330009311 | null | 50.8 | Curative (C) | null | 2015-09-23 | Cladribine IV (5 day) | N | null | 330012831 | RMS 2005 TRIAL |
| 330009271 | 330006079 | 1.74 | 70.1 | null | 2017-06-22 | 2017-06-22 | CHLORAMBUCIL + RITUXIMAB | Y | N | 330012831 | HYDROXYCARBAMIDE |
| 330009272 | 330006079 | 1.65 | null | Curative (C) | 2016-12-18 | 2017-01-03 | Dox + HD Mtx (post PAM) | 02 | N | 330012831 | IMATINIB |
| 330009273 | 330006079 | 1.66 | -1 | Palliative (P) | 2017-09-23 | 2017-10-30 | BUSULFAN + MELPHALAN | 02 | N | 330012831 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330009274 | 330006080 | 1.54 | 117.05 | Palliative (P) | 2017-11-16 | 2018-02-07 | Erlotinib | N | N | 330015056 | DACARBAZINE |
| 330009275 | 330009313 | 1.66 | 63.4 | Palliative (P) | null | 2016-06-12 | CNS LGG Irinotecan & Bevacizumab | N | N | 330015056 | DOXORUBICIN + HD MTX |
| 330009276 | 330006083 | 1.79 | 50.7 | Adjuvant (A) | 2019-06-09 | 2019-07-11 | ETOPOSIDE + MELPHALAN | null | N | 330015148 | RUXOLITINIB |
| 330009277 | 330011071 | 1.87 | 0 | Curative (C) | 2013-06-09 | 2013-06-09 | CETUXIMAB + CISPLATIN + FU | N | N | 330015213 | CYTARABINE |
| 330009278 | 330006086 | 1.67 | null | Neo-adjuvant (N) | 2016-01-07 | 2016-01-12 | DACTINOMYCIN | 02 | N | 330015218 | EMA/CO |
| 330009279 | 330006087 | 1.78 | 68.1 | Palliative (P) | 2016-06-22 | 2016-06-22 | Vincristine (weekly) | 2 | N | 330015310 | BEP |
| 330009280 | 330006090 | null | 78.4 | null | 2015-11-09 | 2015-11-09 | IPO | Y | N | 330015325 | TRIPLE INTRATHECAL |
| 330009281 | 330009317 | 1.77 | 40 | Curative (C) | 2014-12-21 | 2014-12-28 | BEP 5 Day | Y | N | 330015325 | UKALL 2011 |
| 330009282 | 330006092 | 1.79 | 96.1 | Adjuvant (A) | 2016-12-12 | 2016-12-15 | Mitotane 2g | N | N | 330015442 | EMA |
| 330009283 | 330009318 | 0 | 74.9 | Disease modification (D) | 2013-11-24 | 2013-12-19 | IMATINIB | 2 | N | 330015442 | ALL INTENSIFICATION MTX |